{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T03:25:38Z","timestamp":1787109938330,"version":"build-2736575974"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.critrevonc.2026.105472","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:35:59Z","timestamp":1783632959000},"page":"105472","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Neoadjuvant therapy for NSCLC: From monotherapy to precision combination therapy"],"prefix":"10.1016","volume":"225","author":[{"given":"Qianshuo","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaishang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7021-3939","authenticated-orcid":false,"given":"Peiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangnan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.critrevonc.2026.105472_bib1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.5306\/wjco.v13.i5.314","article-title":"Neoadjuvant treatment in non-small cell lung cancer: New perspectives with the incorporation of immunotherapy","volume":"13","author":"Aguado","year":"2022","journal-title":"World J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105472_bib2","first-page":"749","volume":"10","author":"Al-Musawi","year":"2018","journal-title":"Folated-nanocarrier paclitaxel Drug. Deliv. Leuk. Cancer Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105472_bib3","doi-asserted-by":"crossref","DOI":"10.1063\/5.0092330","article-title":"Nanoformulation of intelligence polymeric nanocarrier for resveratrol targeted delivery and study its cytotoxic, apoptotic, and genetics effects in epidermoid carcinoma therapy","volume":"2437","author":"Alnasraui","year":"2022","journal-title":"AIP Conf. Proc."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105472_bib4","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S1470-2045(21)00149-2","article-title":"Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial","volume":"22","author":"Altorki","year":"2021","journal-title":"Lancet Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105472_bib5","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1158\/1078-0432.CCR-24-1561","article-title":"Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY)","volume":"30","author":"Aokage","year":"2024","journal-title":"Clinical cancer research official journal American Association Cancer Research"},{"issue":"Pt 2","key":"10.1016\/j.critrevonc.2026.105472_bib6","article-title":"A comprehensive review of immune checkpoint inhibitors for cancer treatment","volume":"143","author":"Arafat Hossain","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105472_bib7","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1200\/JCO-24-02239","article-title":"Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer","volume":"43","author":"Awad","year":"2025","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105472_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009799","article-title":"Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study","volume":"12","author":"Bahce","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105472_bib9","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1038\/s41467-023-40349-z","article-title":"Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study","volume":"14","author":"Bian","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105472_bib10","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1038\/s41467-025-58435-9","article-title":"Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial","volume":"16","author":"Bian","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105472_bib11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105472_bib12","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105472_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005320","article-title":"Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy","volume":"10","author":"Casarrubios","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105472_bib14","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1038\/s41467-021-25188-0","article-title":"Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer","volume":"12","author":"Cascone","year":"2021","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105472_bib15","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial","volume":"27","author":"Cascone","year":"2021","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105472_bib16","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41591-022-02189-0","article-title":"Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial","volume":"29","author":"Cascone","year":"2023","journal-title":"Nat. Med."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105472_bib17","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative Nivolumab in Resectable Lung Cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"New. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105472_bib18","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1038\/s41591-025-03746-z","article-title":"Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial","volume":"31","author":"Cascone","year":"2025","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105472_bib19","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/s41591-022-01962-5","article-title":"Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial","volume":"28","author":"Chaft","year":"2022","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105472_bib20","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/oncolo\/oyae107","article-title":"The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC","volume":"29","author":"Chang","year":"2024","journal-title":"oncologist"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105472_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007854","article-title":"Epithelium\/imcDC2 axis facilitates the resistance of neoadjuvant anti-PD-1 in human NSCLC","volume":"12","author":"Chen","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105472_bib22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12943-025-02287-w","article-title":"Single-cell and spatial transcriptomic analyses revealing tumor microenvironment remodeling after neoadjuvant chemoimmunotherapy in non-small cell lung cancer","volume":"24","author":"Cui","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105472_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-pathol-011110-130206","article-title":"EGFR mutations and lung cancer","volume":"6","author":"da Cunha Santos","year":"2011","journal-title":"Annu. Rev. Pathol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105472_bib24","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1016\/S1470-2045(15)00077-7","article-title":"Genomic alterations in lung adenocarcinoma","volume":"16","author":"Devarakonda","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105472_bib25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.lungcan.2021.01.018","article-title":"Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience","volume":"153","author":"Eichhorn","year":"2021","journal-title":"Lung cancer (Amsterdam Netherlands)"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105472_bib26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s12026-024-09573-7","volume":"73","author":"Esen","year":"2024","journal-title":"Immunol. Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105472_bib27","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.6004\/jnccn.2019.0059","article-title":"NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020","volume":"17","author":"Ettinger","year":"2019","journal-title":"Journal National Comprehensive Cancer Network JNCCN"},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105472_bib28","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 Blockade in Resectable Lung Cancer","volume":"378","author":"Forde","year":"2018","journal-title":"New. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105472_bib29","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"Forde","year":"2022","journal-title":"New. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105472_bib30","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa2502931","article-title":"Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer","volume":"393","author":"Forde","year":"2025","journal-title":"New. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105472_bib31","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"New. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105472_bib32","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.annonc.2021.12.012","article-title":"Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study","volume":"33","author":"Gazzah","year":"2022","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"9577","key":"10.1016\/j.critrevonc.2026.105472_bib33","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(07)60714-4","article-title":"Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22\/NVALT 2\/EORTC 08012 multicentre randomised trial and update of systematic review","volume":"369","author":"Gilligan","year":"2007","journal-title":"Lancet (Lond. Engl. )"},{"key":"10.1016\/j.critrevonc.2026.105472_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104080","article-title":"Neoadjuvant therapy in non-small cell lung cancer","volume":"190","author":"Grant","year":"2023","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105472_bib35","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-015-0533-4","article-title":"Osimertinib: First Global Approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105472_bib36","article-title":"Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response","volume":"5","author":"Gu\u00e9gan","year":"2024","journal-title":"Cell. Rep. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105472_bib37","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cllc.2021.04.006","article-title":"Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non-small-cell Lung Cancer: SQUAT trial (WJOG 12119L)","volume":"22","author":"Hamada","year":"2021","journal-title":"Clin. lung Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105472_bib38","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jtho.2025.03.051","article-title":"Neoadjuvant Concurrent Chemo-Immuno-Radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage III N2 NSCLC: Primary Results From the SQUAT Trial (WJOG 12119L)","volume":"20","author":"Hamada","year":"2025","journal-title":"Journal thoracic oncology official publication International Association Study Lung Cancer"},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105472_bib39","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO-25-00883","article-title":"Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer","volume":"43","author":"He","year":"2025","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105472_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009301","article-title":"Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings","volume":"12","author":"Henick","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105472_bib41","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"New. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105472_bib42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13073-023-01164-9","article-title":"Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing","volume":"15","author":"Hu","year":"2023","journal-title":"Genome Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105472_bib43","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1186\/s12916-025-04250-4","article-title":"Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA-IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial","volume":"23","author":"Ji","year":"2025","journal-title":"BMC Med."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105472_bib44","first-page":"6638","article-title":"FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review. Clinical cancer research: an official journal of the American Association for","volume":"27","author":"Koch","year":"2021","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105472_bib45","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jtcvs.2022.07.017","article-title":"Surgical resection after neoadjuvant durvalumab and radiation is feasible and safe in non-small cell lung cancer: Results from a randomized trial","volume":"165","author":"Lee","year":"2023","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105472_bib46","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jtho.2024.12.023","article-title":"Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA)","volume":"20","author":"Lee","year":"2025","journal-title":"Journal thoracic oncology official publication International Association Study Lung Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105472_bib47","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.jtho.2023.07.006","article-title":"Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives","volume":"18","author":"Lee","year":"2023","journal-title":"Journal thoracic oncology official publication International Association Study Lung Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105472_bib48","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105472_bib49","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer","volume":"386","author":"Li","year":"2022","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105472_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110316","article-title":"Neoadjuvant low-dose radiotherapy plus durvalumab and chemotherapy for potentially resectable stage III NSCLC: A phase Ib dose-escalation study","volume":"196","author":"Li","year":"2024","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105472_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2018.02.006","article-title":"Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies","volume":"65","author":"Lim","year":"2018","journal-title":"Cancer Treat. Rev."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105472_bib52","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1158\/2159-8290.CD-24-0231","article-title":"NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations","volume":"14","author":"Lin","year":"2024","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105472_bib53","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1186\/s12916-025-04419-x","article-title":"The role of dynamic monitoring of plasma cell-free DNA methylation in predicting pathological response in resectable stage IIB-IIIB non-small cell lung cancer: biomarker analyses from a prospective phase II trial","volume":"23","author":"Liu","year":"2025","journal-title":"BMC Med."},{"key":"10.1016\/j.critrevonc.2026.105472_bib54","article-title":"Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105472_bib55","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41392-023-01700-4","article-title":"Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study","volume":"8","author":"Liu","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105472_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108676","article-title":"Icotinib plus chemotherapy as neoadjuvant treatment for resectable stage II-IIIB EGFR-mutant lung adenocarcinoma: a phase II study (NEOIPOWER)","volume":"206","author":"Lu","year":"2025","journal-title":"Lung cancer (Amsterdam Netherlands)"},{"key":"10.1016\/j.critrevonc.2026.105472_bib57","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.lungcan.2023.02.011","article-title":"Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial","volume":"178","author":"Lv","year":"2023","journal-title":"Lung cancer (Amsterdam Netherlands)"},{"key":"10.1016\/j.critrevonc.2026.105472_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108457","article-title":"Long-term outcomes of neoadjuvant gefitinib in resectable stage II-IIIA non-small cell lung cancer: A phase II, prospective cohort study","volume":"201","author":"Ma","year":"2025","journal-title":"Lung cancer (Amsterdam Netherlands)"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105472_bib59","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12935-023-02902-0","article-title":"Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired","volume":"23","author":"Marei","year":"2023","journal-title":"Cancer Cell. Int."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105472_bib60","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jtho.2025.06.015","article-title":"Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC","volume":"20","author":"Mitsudomi","year":"2025","journal-title":"Journal thoracic oncology official publication International Association Study Lung Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105472_bib61","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin. Proc."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105472_bib62","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijrobp.2023.03.042","article-title":"Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and\/or Surgery in Stage III Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study","volume":"117","author":"Peled","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105472_bib63","first-page":"350","article-title":"Effects of Neoadjuvant Therapy After the Initial Assessment of Operability in Patients with Borderline Operable and Inoperable Stage IIIA Non-small Lung Cancer","volume":"74","author":"Pilav","year":"2020","journal-title":"Med. Arch. (Sarajevo Bosnia Herzeg. )"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105472_bib64","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol."},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105472_bib65","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1200\/JCO.21.02660","article-title":"Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)","volume":"40","author":"Provencio","year":"2022","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105472_bib66","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S1470-2045(24)00498-4","article-title":"Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial","volume":"25","author":"Provencio","year":"2024","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105472_bib67","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41392-025-02408-3","article-title":"Consolidative nivolumab versus observation in unresectable stage III non-small cell lung cancer patients following neoadjuvant nivolumab plus chemotherapy and concurrent chemoradiotherapy (CA209-7AL): a randomized clinical trial","volume":"10","author":"Qiu","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105472_bib68","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/cac2.12197","article-title":"Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020","volume":"41","author":"Qiu","year":"2021","journal-title":"Cancer communications (London England)"},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105472_bib69","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"New. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105472_bib70","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1056\/NEJM199401203300301","article-title":"A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer","volume":"330","author":"Rosell","year":"1994","journal-title":"New. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105472_bib71","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1001\/jamaoncol.2024.1897","article-title":"Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial","volume":"10","author":"Ross","year":"2024","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105472_bib72","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/jnci\/86.9.673","article-title":"A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer","volume":"86","author":"Roth","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105472_bib73","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1038\/s41467-025-63696-5","article-title":"Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy","volume":"16","author":"Schmid","year":"2025","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105472_bib74","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41591-024-02965-0","article-title":"Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial","volume":"30","author":"Schuler","year":"2024","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105472_bib75","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.jtcvs.2022.01.019","article-title":"Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer","volume":"164","author":"Sepesi","year":"2022","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105472_bib76","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105472_bib77","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"New. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105472_bib78","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S1470-2045(20)30140-6","article-title":"Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Shu","year":"2020","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105472_bib79","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA a cancer journal clinicians"},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105472_bib80","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"New. Engl. J. Med."},{"issue":"7153","key":"10.1016\/j.critrevonc.2026.105472_bib81","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"issue":"50","key":"10.1016\/j.critrevonc.2026.105472_bib82","doi-asserted-by":"crossref","first-page":"19893","DOI":"10.1073\/pnas.0805381105","article-title":"A mouse model for EML4-ALK-positive lung cancer","volume":"105","author":"Soda","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105472_bib83","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol."},{"issue":"29","key":"10.1016\/j.critrevonc.2026.105472_bib84","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study","volume":"42","author":"Solomon","year":"2024","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105472_bib85","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"New. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105472_bib86","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.atssr.2022.11.014","article-title":"Neoadjuvant Targeted Therapy in Non-Small Cell Lung Cancer and Its Impact on Surgical Outcomes","volume":"1","author":"Sorin","year":"2023","journal-title":"Ann. Thorac. Surg. Short. Rep."},{"issue":"10459","key":"10.1016\/j.critrevonc.2026.105472_bib87","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet (Lond. Engl. )"},{"key":"10.1016\/j.critrevonc.2026.105472_bib88","article-title":"Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials","volume":"10","author":"Sun","year":"2020","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105472_bib89","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA a cancer journal clinicians"},{"key":"10.1016\/j.critrevonc.2026.105472_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102195","article-title":"Clinical efficacies of different neoadjuvant therapies for non-small cell lung cancer","volume":"51","author":"Tan","year":"2025","journal-title":"Transl. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105472_bib91","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/RLU.0000000000005910","article-title":"Prognostic Value of 18F-FDG PET\/CT in Neoadjuvant PD-1 Inhibitor-treated NSCLC: A Five-year Follow-up Study","volume":"50","author":"Tao","year":"2025","journal-title":"Clin. Nucl. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105472_bib92","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jtho.2020.05.020","article-title":"Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches","volume":"15","author":"Uprety","year":"2020","journal-title":"Journal thoracic oncology official publication International Association Study Lung Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105472_bib93","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"New. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105472_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102040","article-title":"Neoadjuvant nivolumab plus chemotherapy versus chemotherapy for resectable NSCLC: subpopulation analysis of Chinese patients in CheckMate 816","volume":"8","author":"Wang","year":"2023","journal-title":"ESMO Open."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105472_bib95","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","article-title":"Toward personalized treatment approaches for non-small-cell lung cancer","volume":"27","author":"Wang","year":"2021","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105472_bib96","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.21037\/tlcr-2025-426","article-title":"Efficacy and safety of perioperative, adjuvant and neoadjuvant chemoimmunotherapy stratified by clinical stage and PD-L1 expression in resectable non-small cell lung cancer: a systematic review and network meta-analysis","volume":"14","author":"Wang","year":"2025","journal-title":"Transl. lung Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105472_bib97","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010395","article-title":"Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis","volume":"13","author":"Wood","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105472_bib98","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jtcvs.2024.05.006","article-title":"Predicting therapeutic response to neoadjuvant immunotherapy based on an integration model in resectable stage IIIA (N2) non-small cell lung cancer","volume":"169","author":"Xu","year":"2025","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105472_bib99","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jtho.2022.09.222","article-title":"Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial","volume":"18","author":"Yan","year":"2023","journal-title":"Journal thoracic oncology official publication International Association Study Lung Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105472_bib100","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/s41467-025-57184-z","article-title":"Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial","volume":"16","author":"Yi","year":"2025","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105472_bib101","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.annonc.2024.02.003","article-title":"Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC","volume":"35","author":"Yu","year":"2024","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105472_bib102","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jtho.2018.10.161","article-title":"Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement","volume":"14","author":"Zhang","year":"2019","journal-title":"Journal thoracic oncology official publication International Association Study Lung Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105472_bib103","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/j.jtho.2019.12.133","article-title":"Feasibility and Safety of Neoadjuvant Alectinib in a Patient With ALK-Positive Locally Advanced NSCLC","volume":"15","author":"Zhang","year":"2020","journal-title":"Journal thoracic oncology official publication International Association Study Lung Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105472_bib104","article-title":"Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE\/CTONG2104)","volume":"5","author":"Zhang","year":"2024","journal-title":"Cell. Rep. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105472_bib105","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jtho.2022.04.012","article-title":"Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC","volume":"17","author":"Zhang","year":"2022","journal-title":"Journal thoracic oncology official publication International Association Study Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105472_bib106","article-title":"Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105472_bib107","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.jtho.2023.02.019","article-title":"Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial","volume":"18","author":"Zhao","year":"2023","journal-title":"Journal thoracic oncology official publication International Association Study Lung Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105472_bib108","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1996000","article-title":"Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer","volume":"10","author":"Zhao","year":"2021","journal-title":"Oncoimmunology"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105472_bib109","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S2213-2600(24)00215-7","article-title":"Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial","volume":"12","author":"Zhao","year":"2024","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105472_bib110","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41392-022-01286-3","article-title":"Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial","volume":"8","author":"Zhong","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105472_bib111","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.ccell.2024.05.024","article-title":"Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial","volume":"42","author":"Zhou","year":"2024","journal-title":"Cancer Cell."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105472_bib112","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1007\/s00259-025-07115-3","article-title":"Efficacy of radiolabelled PD-L1-targeted nanobody in predicting and evaluating the combined immunotherapy and chemotherapy for resectable non-small cell lung cancer","volume":"52","author":"Zhou","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105472_bib113","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1186\/s12916-022-02696-4","article-title":"Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial","volume":"20","author":"Zhu","year":"2022","journal-title":"BMC Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:39:09Z","timestamp":1787107149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":113,"alternative-id":["S1040842826003598"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105472","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant therapy for NSCLC: From monotherapy to precision combination therapy","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105472","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105472"}}